These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

224 related items for PubMed ID: 21397972

  • 1. Plasma versus serum levels of osteopontin and mesothelin in patients with malignant mesothelioma--which is best?
    Creaney J, Yeoman D, Musk AW, de Klerk N, Skates SJ, Robinson BW.
    Lung Cancer; 2011 Oct; 74(1):55-60. PubMed ID: 21397972
    [Abstract] [Full Text] [Related]

  • 2. Comparison of osteopontin, megakaryocyte potentiating factor, and mesothelin proteins as markers in the serum of patients with malignant mesothelioma.
    Creaney J, Yeoman D, Demelker Y, Segal A, Musk AW, Skates SJ, Robinson BW.
    J Thorac Oncol; 2008 Aug; 3(8):851-7. PubMed ID: 18670302
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Mesothelin and osteopontin as circulating markers of diffuse malignant peritoneal mesothelioma: A preliminary study.
    Bruno F, Baratti D, Martinetti A, Morelli D, Sottotetti E, Bonini C, Guaglio M, Kusamura S, Deraco M.
    Eur J Surg Oncol; 2018 Jun; 44(6):792-798. PubMed ID: 29503128
    [Abstract] [Full Text] [Related]

  • 6. Combined serum mesothelin and plasma osteopontin measurements in malignant pleural mesothelioma.
    Cristaudo A, Bonotti A, Simonini S, Vivaldi A, Guglielmi G, Ambrosino N, Chella A, Lucchi M, Mussi A, Foddis R.
    J Thorac Oncol; 2011 Sep; 6(9):1587-93. PubMed ID: 21642872
    [Abstract] [Full Text] [Related]

  • 7. Midkine is a potential novel marker for malignant mesothelioma with different prognostic and diagnostic values from mesothelin.
    Ak G, Tada Y, Shimada H, Metintas S, Ito M, Hiroshima K, Tagawa M, Metintas M.
    BMC Cancer; 2017 Mar 23; 17(1):212. PubMed ID: 28335760
    [Abstract] [Full Text] [Related]

  • 8. Combination of mesothelin and CEA significantly improves the differentiation between malignant pleural mesothelioma, benign asbestos disease, and lung cancer.
    Muley T, Dienemann H, Herth FJ, Thomas M, Meister M, Schneider J.
    J Thorac Oncol; 2013 Jul 23; 8(7):947-51. PubMed ID: 23777840
    [Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Combined CA125 and mesothelin levels for the diagnosis of malignant mesothelioma.
    Creaney J, van Bruggen I, Hof M, Segal A, Musk AW, de Klerk N, Horick N, Skates SJ, Robinson BW.
    Chest; 2007 Oct 23; 132(4):1239-46. PubMed ID: 17646232
    [Abstract] [Full Text] [Related]

  • 11. Biomarkers for malignant pleural mesothelioma: a meta-analysis.
    Gillezeau CN, van Gerwen M, Ramos J, Liu B, Flores R, Taioli E.
    Carcinogenesis; 2019 Nov 25; 40(11):1320-1331. PubMed ID: 31169881
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma.
    Bonotti A, Simonini S, Pantani E, Giusti L, Donadio E, Mazzoni MR, Chella A, Marconi L, Ambrosino N, Lucchi M, Mussi A, Cristaudo A, Foddis R.
    Int J Biol Markers; 2017 Mar 02; 32(1):e126-e131. PubMed ID: 27646775
    [Abstract] [Full Text] [Related]

  • 15. Serum and pleural fluid biomarkers for mesothelioma.
    Creaney J, Robinson BW.
    Curr Opin Pulm Med; 2009 Jul 02; 15(4):366-70. PubMed ID: 19417672
    [Abstract] [Full Text] [Related]

  • 16. Comparison of the diagnostic accuracy of the MSLN gene products, mesothelin and megakaryocyte potentiating factor, as biomarkers for mesothelioma in pleural effusions and serum.
    Creaney J, Sneddon S, Dick IM, Dare H, Boudville N, Musk AW, Skates SJ, Robinson BW.
    Dis Markers; 2013 Jul 02; 35(2):119-27. PubMed ID: 24167356
    [Abstract] [Full Text] [Related]

  • 17. Serum mesothelin for diagnosing malignant pleural mesothelioma: an individual patient data meta-analysis.
    Hollevoet K, Reitsma JB, Creaney J, Grigoriu BD, Robinson BW, Scherpereel A, Cristaudo A, Pass HI, Nackaerts K, Rodríguez Portal JA, Schneider J, Muley T, Di Serio F, Baas P, Tomasetti M, Rai AJ, van Meerbeeck JP.
    J Clin Oncol; 2012 May 01; 30(13):1541-9. PubMed ID: 22412141
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Pleural effusion hyaluronic acid as a prognostic marker in pleural malignant mesothelioma.
    Creaney J, Dick IM, Segal A, Musk AW, Robinson BW.
    Lung Cancer; 2013 Dec 01; 82(3):491-8. PubMed ID: 24161718
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.